Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis

The Pharmacogenomics Journal volume 19, pages 286–294 (2019)Cite this article

Subjects

Abstract

Methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are life-threatening adverse drug reactions. Based on previous studies, HLA genotypes may play an important role in methazolamide-induced SJS/TEN. Therefore, to identify the associations between HLA genotypes and methazolamide-induced cutaneous adverse drug reactions (cADRs) (i.e., SJS/TEN and hypersensitivity syndrome), a systematic review and meta-analysis were performed. Two studies (one study in Korean and another in Han Chinese) met the inclusion criteria. The studies included 13 patients with methazolamide-induced SJS/TEN, 30 methazolamide-tolerant, and 768 population controls. Associations between HLA-B*5901, HLA-B*5901-Cw*0102 haplotype, and methazolamide-induced SJS/TEN were identified in methazolamide-tolerant and population controls. Overall ORs were 305.0 (95% CI = 11.3–8, 259.4) in methazolamide-tolerant and 715.3 (95% CI = 83.1–6,158.5) in population control. In addition, statistically significant associations between the HLA-Cw*0102 and methazolamide-induced SJS/TEN were found in methazolamide-tolerant (OR = 12.1; 95% CI = 1.3–111.7) and population control (OR = 17.5; 95% CI = 3.2–96.6). Since HLA-B*5901 and HLA-B*5901-Cw*0102 haplotype are associated with methazolamide-induced SJS/TEN, genetic screening prior to methazolamide therapy in Asian populations is warranted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16:730–42.

    CAS  PubMed  Google Scholar 

  2. PubChem Compound Database [Internet]. National Center for Biotechnology Information. [cited December 21, 2017]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/4100.

  3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–85.

    Article  CAS  Google Scholar 

  4. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Clinical reviews in allergy & immunology. 2018;54:147–76.

    Article  Google Scholar 

  5. Ergen EN, Hughey LC. Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. 2017;153:1344.

    Article  Google Scholar 

  6. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123–9.

    Article  CAS  Google Scholar 

  7. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16:475–93.

    Article  Google Scholar 

  8. Oliveira A, Sanches M, Selores M. Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Med Port. 2011;24(Suppl 4):995–1002.

    PubMed  Google Scholar 

  9. Arantes LB, Reis CS, Novaes AG, Carvalho MR, Gottems LBD, Novaes M. Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals. Bras Dermatol. 2017;92:661–7.

    Article  Google Scholar 

  10. Bharadwaj M, Illing P, Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Pers Med. 2010;7:495–516.

    Article  CAS  Google Scholar 

  11. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharm Genom. 2008;18:99–107.

    Article  CAS  Google Scholar 

  12. Illing PT, Purcell AW, McCluskey J. The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics. 2017;69:617–30.

    Article  CAS  Google Scholar 

  13. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:1025–32.

    Article  CAS  Google Scholar 

  14. Mondino BJ, Brown SI, Biglan AW. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol (Chic, Ill: 1960). 1982;100:1453–4.

    Article  CAS  Google Scholar 

  15. Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens. 1986;28:251–4.

    Article  CAS  Google Scholar 

  16. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123:1171–3.

    Article  CAS  Google Scholar 

  17. Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharm Genom. 2015;25:402–11.

    Article  CAS  Google Scholar 

  18. Rufini S, Ciccacci C, Politi C, Giardina E, Novelli G, Borgiani P. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics. 2015;16:1989–2002.

    Article  CAS  Google Scholar 

  19. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

    Article  Google Scholar 

  20. Su SC, Hung SI, Fan WL, Dao RL, Chung WH. Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation. Int J Mol Sci. 2016;17:1890.

    Article  Google Scholar 

  21. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: key regulators of T-cell-mediated drug hypersensitivity. HLA. 2018;91:3–16.

    Article  CAS  Google Scholar 

  22. White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. J Allergy Clin Immunol Pract. 2018;6:38–69.

    Article  Google Scholar 

  23. Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, et al. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010;51:297–300.

    Article  Google Scholar 

  24. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011;364:1126–33.

    Article  CAS  Google Scholar 

  25. Tiamkao S, Jitpimolmard J, Sawanyawisuth K, Jitpimolmard S. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm. 2013;35:608–12.

    Article  Google Scholar 

  26. Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS ONE. 2014;9:e94294.

    Article  Google Scholar 

  27. Chong HY, Lim YH, Prawjaeng J, Tassaneeyakul W, Mohamed Z, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharm Genom. 2018;28:56–67.

    CAS  Google Scholar 

  28. Mushiroda T, Takahashi Y, Onuma T, Yamamoto Y, Kamei T, Hoshida T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurology. 2018;75:842–9.

    Article  Google Scholar 

  29. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;7:317–23.

    Article  CAS  Google Scholar 

  30. Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12:118.

    Article  CAS  Google Scholar 

  31. Tangamornsuksan W, Lohitnavy O, Kongkaew C, Chaiyakunapruk N, Reisfeld B, Scholfield NC, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68–76.

    Article  CAS  Google Scholar 

  32. Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology. 2017;88:78–86.

    Article  CAS  Google Scholar 

  33. Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. J Pharm Pharm Sci. 2018;21:1–18.

    Article  Google Scholar 

  34. Rijal JP, Pompa T, Giri S, Bhatt VR. A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole. BMJ Case Rep. 2014;2014:bcr2013203163.

    Google Scholar 

  35. Flach AJ, Smith RE, Fraunfelder FT. Stevens-Johnson syndrome associated with methazolamide treatment reported in two Japanese-American women. Ophthalmology. 1995;102:1677–80.

    Article  CAS  Google Scholar 

  36. Cotter JB. Methazolamide-induced Stevens-Johnson syndrome: a warning! Arch Ophthalmol (Chic, Ill: 1960). 1998;116:117.

    Article  CAS  Google Scholar 

  37. Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. J Dermatol. 2011;38:272–5.

    Article  Google Scholar 

  38. Carroll OM, Bryan PA, Robinson RJ. Stevens-Johnson syndrome associated with long-acting sulfonamides. JAMA. 1966;195:691–3.

    Article  CAS  Google Scholar 

  39. Xu Y, Wu M, Sheng F, Sun Q. Methazolamide-induced toxic epidermal necrolysis in a Chinese woman with HLA-B5901. Indian J Ophthalmol. 2015;63:623–4.

    Article  Google Scholar 

  40. Shu C, Shu D, Tie D, Yu M, Zhang R, Wang T, et al. Toxic epidermal necrolysis induced by methazolamide in a Chinese-Korean man carrying HLA-B*59:01. Int J Dermatol. 2015;54:1242–5.

    Article  CAS  Google Scholar 

  41. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol (Chic, Ill: 1960). 1997;115:550–3.

    Article  CAS  Google Scholar 

  42. Moon JI, Seo JH, Park CK. Association of HLA type with Stevens-Johnson syndrome induced by methazolamide treatment. J Korean Ophthalmol Soc. 2000;41:2241.

    Google Scholar 

  43. Sung KH, Jeong Y, Choi HU, Lee SK. Two cases of HLA-B59(+) Stevens-Johnson syndrome-toxic epidermal necrolysis associated with methazolamide treatment. Korean J Dermatol. 2005;43:561–3.

    Google Scholar 

  44. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11:879–84.

    Article  CAS  Google Scholar 

  45. Yang F, Yang Y, Zhu Q, Chen SA, Fu X, Yan S, et al. Research on susceptible genes and immunological pathogenesis of cutaneous adverse drug reactions in Chinese Hans. J Investig Dermatol Symp Proc. 2015;17:29–31.

    Article  CAS  Google Scholar 

  46. Yang F, Xuan J, Chen J, Zhong H, Luo H, Zhou P, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharm J. 2016;16:83–7.

    CAS  Google Scholar 

  47. Cheon M, Lee YB, Yu DS, Kim JW. Toxic epidermal necrolysis in a patient with HLA-B*5901 haplotype caused by topical and oral carbonic anhydrase inhibitors. Ann Dermatol. 2014;26:645–6.

    Article  Google Scholar 

  48. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291–306.

    Article  Google Scholar 

  49. Smits K, Schouten J, Smits L, Stelma F, Nelemans P, Prins M. A review on the design and reporting of studies on drug-gene interaction. J Clin Epidemiol. 2005;58:651–4.

    Article  Google Scholar 

  50. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2011. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  51. Szumilas M. Explaining odds ratios. J Can Acad Child Adolescent Psychiatry. 2010;19:227–9.

    Article  Google Scholar 

  52. Callcut RA, Branson RD. How to read a review paper. Respir Care. 2009;54:1379–85.

    PubMed  Google Scholar 

  53. Zlowodzki M, Poolman RW, Kerkhoffs GM, Tornetta P 3rd, Bhandari M. How to interpret a meta-analysis and judge its value as a guide for clinical practice. Acta Orthop. 2007;78:598–609.

    Article  Google Scholar 

  54. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  Google Scholar 

  55. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

    Article  Google Scholar 

  56. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  Google Scholar 

  57. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.

    Article  CAS  Google Scholar 

  58. The Allele Frequency Net Database [Internet]. 2015 [cited December 20, 2017]. Available from: http://www.allelefrequencies.net.

  59. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 2015;43(Database issue):D784–8.

    Article  CAS  Google Scholar 

  60. Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol. 2018;154:441–6.

    Article  Google Scholar 

  61. Tempark T, Satapornpong P, Rerknimitr P, Nakkam N, Saksit N, Wattanakrai P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharm Genom. 2017;27:429–37.

    Article  CAS  Google Scholar 

  62. Kim JW, Shin SY. Toxic epidermal necrolysis and Stevens-Johnson syndrome caused by topical ophthalmic use of dorzolamid. Korean. J Dermatol. 2009;27:317–21.

    Article  Google Scholar 

  63. Lee JHLS, Kim YH. A case of Stevens-Johnson syndrome after acetazolamide use. J Korean Ophthalmol Soc. 1998;39:216–20.

    Google Scholar 

  64. Chun JS, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. Toxic epidermal necrolysis induced by the topical carbonic anhydrase inhibitors brinzolamide and dorzolamide. Ann Dermatol. 2008;20:260–2.

    Article  Google Scholar 

  65. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005;65:437–47.

    Article  CAS  Google Scholar 

Download references

Author contributions

Ms. Tangamornsuksan and Dr. Lohitnavy had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Ms. Tangamornsuksan and Dr. Lohitnavy. Acquisition, analysis, and interpretation of data: Ms. Tangamornsuksan and Dr. Lohitnavy. Drafting of the manuscript: Ms. Tangamornsuksan and Dr. Lohitnavy. Critical revision of the manuscript for important intellectual content: Dr. Lohitnavy. Statistical analysis: Ms. Tangamornsuksan. Obtained funding: not applicable. Administrative, technical, or material support: not applicable. Study supervision: Dr. Lohitnavy.

Author information

Authors and Affiliations

  1. Center of Excellence for Environmental Health & Toxicology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

    Wimonchat Tangamornsuksan & Manupat Lohitnavy

  2. Pharmacokinetic Research Unit, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

    Manupat Lohitnavy

  3. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand

    Wimonchat Tangamornsuksan & Manupat Lohitnavy

Authors
  1. Wimonchat Tangamornsuksan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manupat Lohitnavy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manupat Lohitnavy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tangamornsuksan, W., Lohitnavy, M. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. Pharmacogenomics J 19, 286–294 (2019). https://doi.org/10.1038/s41397-018-0052-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-018-0052-2

This article is cited by

Search

Advanced search

Quick links